Fever News and Research

RSS

NIH awards two new grants to develop Avidocin platform

AvidBiotics today announced the receipt of two new grants totaling $1 million dollars from the National Institutes of Health that further the development of the company's novel Avidocin™ platform for narrow spectrum antibacterial proteins against important health care threats. These grants add to three previous grants covering AvidBiotics' anti-infectious disease technologies, which provide approximately $3.4 million in currently active funding for the company.

15 Oct 2010

Acetadote Injection is now commercially available in Australia

Cumberland Pharmaceuticals Inc. and Phebra Pty Ltd. today announced that Acetadote (acetylcysteine) Injection, an injectable product used to treat acetaminophen (paracetamol) overdose, is now commercially available in the Australian market. Phebra Pty Ltd., an Australian-based specialty pharmaceutical company, has an exclusive license from U.S.-based Cumberland Pharmaceuticals to market and distribute the product in Australia.

15 Oct 2010

NanoViricides files financial year end annual report with SEC

NanoViricides, Inc. reports that it has filed its financial year end annual report (Form 10K) with the Securities and Exchange Commission (SEC) yesterday in a timely manner.

14 Oct 2010

Officials discuss leadership, donor commitments, eliminating leprosy at start of WHO Western Pacific Region Committee Session

The WHO "must demonstrate strong leadership backed by impeccable technical competency, [Malaysian] Prime Minister Datuk Seri Najib Tun Razak said" at the opening ceremony of the 61st Session of the WHO Regional Committee for the Western Pacific Monday, Bernama reports.

13 Oct 2010

WHO Western Pacific meeting to address maternal health, rise in dengue

Maternal health and dengue fever are among the issues that will be discussed at the 61st session of the WHO Regional Committee for the Western Pacific, Bernama reports.

12 Oct 2010

Abbott to withdraw Meridia medicine from the U.S. market

Abbott will voluntarily withdraw Meridia (sibutramine) from the U.S. market at the request of the U.S. Food and Drug Administration (FDA).

11 Oct 2010

Opinions: Learning to live with malaria; U.S. food aid policy; foreign aid reform

Recent discoveries of a possible wild reservoir for humankind's most malignant malaria, some 130 years after the discovery of the malaria parasite, could mean that it will be impossible to eradicate malaria,Sonia Shah, the author of The Fever, How Malaria Has Ruled Humankind for 500,000 Years,observes in an International Herald Tribune opinion piece.

11 Oct 2010

IV ibuprofen effective in reducing fever in hospitalized patients

Cumberland Pharmaceuticals Inc. today announced the publication of data affirming the safety and efficacy of Caldolor (ibuprofen) Injection in treating fever in critically ill and non-critically ill adults. Published in the peer-reviewed journal Critical Care, the study showed that IV ibuprofen was significantly more effective at reducing fever in hospitalized patients than placebo.

8 Oct 2010

Dengue fever spreads in Asia, WHO warns 2.5B people at risk

The WHO "has warned that 2.5 billion people are at risk" of dengue fever, "which has 'grown dramatically in recent decades,'" Agence France-Presse reports. WHO officials cite higher temperatures, growing populations and international travel for the "rapid rise in urban mosquito populations" and in dengue. Seventy percent of the at-risk population is in Asia, the WHO said.

8 Oct 2010

NIAID announces three new contracts to fund research on dengue, anthrax vaccines

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, today announced three new contracts to fund research on vaccines to protect against emerging infectious diseases and biological threats that could be used in a terror attack. Each project focuses on simple and efficient vaccine delivery approaches that could be deployed quickly. The total funding for the three contracts could reach $68 million, depending on the successful completion of defined project milestones.

8 Oct 2010

Inviragen, PharmaJet awarded NIAID contract to develop needle-free, easy to administer dengue vaccine

Inviragen and PharmaJet announced the award of a five year, $15.5 million dollar contract from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to advance the development of a needle-free, easy to administer dengue vaccine. The award will fund preclinical studies, regulatory filings, manufacturing and clinical testing of Inviragen's tetravalent dengue vaccine, DENVax delivered with PharmaJet's convenient needle-free injection device.

8 Oct 2010

FMCNA offers annual flu vaccine to patients and clinical staff

Beginning in mid-October, Fresenius Medical Care North America will offer all of its patients and clinical staff an annual flu vaccine, which protects against both seasonal flu and H1N1 this year. The Centers for Disease Control (CDC) cautions that it is likely that H1N1 will continue to spread along with seasonal viruses this flu season.

5 Oct 2010

CPS recommends all Canadian babies should be vaccinated against rotavirus

All Canadian babies should be vaccinated against rotavirus, according to a new statement by the Canadian Paediatric Society. The CPS is also calling for public funding of the vaccine, which is not currently covered by provincial or territorial health plans.

5 Oct 2010

$3.4M grant for study to distinguish bacterial infections from viral infections in infants with fevers

Octavio Ramilo, MD, chief of Infectious Diseases at Nationwide Children's Hospital, is one of three principal investigators who will share in a five-year, $3.4 million grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development. Dr. Ramilo and a team of more than 50 physicians across the United States are investigating the use of novel technologies for distinguishing between bacterial and viral infections in infants with fevers within emergency departments.

4 Oct 2010

Researchers examine new genes to control mosquito-borne diseases

An Iowa State University researcher searched for new genes that are turned on during infection in a type of mosquito that is not only a pest, but transmits disease-causing pathogens.

4 Oct 2010

Suspected hand, foot and mouth disease on Denver flight

Two children arrived on a flight from Mexico to Denver showing symptoms of the contagious illness called ‘hand, foot and mouth’ disease (HFMD) and were checked by paramedics. They were allowed to leave after experts said they were no threat to public health.

4 Oct 2010

Healthy respect for flu this season

Flu season officially begins Friday, Oct. 1, and unlike last year's season when shortages lead to rationing, there will be plenty of vaccine on hand for everyone who wants a flu shot.

1 Oct 2010

FDA takes action against unapproved single-ingredient oral colchicine

The U.S. Food and Drug Administration took action against companies that manufacture, distribute, and/or market unapproved single-ingredient oral colchicine, a medication commonly used for the daily prevention of gout, to treat acute gout flare-ups, and for the treatment of Familial Mediterranean Fever (FMF).

1 Oct 2010

Research shows dexamethasone treatment effective for bacterial meningitis

New research shows that an intravenous (IV) treatment may cut a person's risk of dying from bacterial meningitis. The research is published in the September 29, 2010, online issue of Neurology, the medical journal of the American Academy of Neurology. The treatment is called dexamethasone.

30 Sep 2010

ZymoGenetics announces positive survival data from IL-21 Phase 2a clinical trial

ZymoGenetics, Inc. today announced positive survival data from a Phase 2a clinical trial in metastatic melanoma with recombinant Interleukin 21 (IL-21) as a single agent. Median overall survival was 12.4 months, and the percentage of patients surviving at 12 months was 53%.

29 Sep 2010